This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertoni, F. Articles by Zucca, E. Search for Related Content PubMed PubMed Citation Articles by Bertoni, F. Articles by Zucca, E. Social Bookmarking                            What's this?

State-of-the-Art Therapeutics: Marginal-Zone Lymphoma

Francesco Bertoni, Emanuele Zucca

From the Laboratory of Experimental Oncology; and the Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Address reprint requests to Emanuele Zucca, MD, Lymphoma Unit, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland; e-mail: emanuelezucca{at}yahoo.com.

Marginal-zone lymphomas comprise the mucosa-associated lymphoid tissue (MALT) type (extranodal marginal-zone lymphoma [EMZL]), the nodal marginal zone B-cell lymphoma (NMZL) and the splenic MZL (SMZL). EMZL is relatively common, whereas the remaining two entities are relatively rare disorders. EMZL, especially in its gastric localization, is the most studied MZL, and there are many data both on the underlying genetic lesions and on the role of infectious agents. These data have determined unique approach among all other lymphoma subtypes: the possibility of treating a subset of patients with antibiotics alone as first line of treatment. Indeed, there is compelling evidence that histologic regressions can be achieved in most gastric MALT lymphomas by eradicating Helicobacter pylori infection. However, molecular follow-up studies showed the persistence of the malignant clone in half of the cases in histologic remission after antibiotic treatment and transient, either histologic or molecular, relapses have been reported, too. Hence, a careful long-term follow-up is mandatory after antibiotic treatment. Radiotherapy, chemotherapy, anti-CD20 monoclonal antibodies are effective alternative therapies. The precise role of surgical resection should be redefined in view of the encouraging results of conservative approaches. Differently from EMZL, both SMLZ and NMZL often present with disseminated disease at diagnosis. The therapeutic approach comprises splenectomy, for SMZL, and chemotherapy, but with no consensus about the best treatment. This review addresses the current knowledge on the clinical features and therapeutic approaches for the individual MZLs.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Stathis, C. Chini, F. Bertoni, I. Proserpio, C. Capella, L. Mazzucchelli, E. Pedrinis, F. Cavalli, G. Pinotti, and E. Zucca Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type Ann. Onc., June 1, 2009; 20(6): 1086 - 1093. [Abstract] [Full Text] [PDF]

				E. Zucca, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv113 - iv114. [Full Text] [PDF]

				A. Psyrri, S. Papageorgiou, and T. Economopoulos Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management Ann. Onc., December 1, 2008; 19(12): 1992 - 1999. [Abstract] [Full Text] [PDF]

				V. M L Cohen, J. Sweetenham, and A. D Singh Ocular adnexal lymphoma. What is the evidence for an infectious aetiology? Br. J. Ophthalmol., April 1, 2008; 92(4): 446 - 448. [Full Text] [PDF]

				J. P. de Boer, R. F. Hiddink, M. Raderer, N. Antonini, B. M. P. Aleman, H. Boot, and D. de Jong Dissemination patterns in non-gastric MALT lymphoma Haematologica, February 1, 2008; 93(2): 201 - 206. [Abstract] [Full Text] [PDF]

				C. M Bacon, M.-Q. Du, and A. Dogan Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists J. Clin. Pathol., April 1, 2007; 60(4): 361 - 372. [Abstract] [Full Text] [PDF]

				E. Zucca and F. Bertoni Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? J Natl Cancer Inst, October 4, 2006; 98(19): 1348 - 1349. [Full Text] [PDF]

				L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use Blood, June 15, 2006; 107(12): 4643 - 4649. [Abstract] [Full Text] [PDF]

				L. Arcaini, S. Burcheri, A. Rossi, F. Passamonti, M. Paulli, E. Boveri, E. Brusamolino, E. Orlandi, A. Molteni, A. Pulsoni, et al. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. Oncologist, March 1, 2006; 11(3): 285 - 291. [Abstract] [Full Text] [PDF]